Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus IMPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus IMPLANON.
ASHLYNA vs IMPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Category C
Category C
Contraceptive
Contraceptive